BioSpace News Archive

HiberCell, Inc. is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC).

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird’s 2024 Global Consumer, Technology & Services Conference on Wednesday, June 5, 2024, in New York, NY.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced plans to participate in the upcoming Bank of America Healthcare Conference.

Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2024.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows.

Journey Medical Corporation, a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration -approved prescription pharmaceutical products for the treatment of dermatological conditions, announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 72,700 restricted stock units to five newly-hired employees.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter ended March 31, 2024.

Penumbra, Inc. announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.